mal-peg4-val-cit-pab-oh

Mal-PEG4-Val-Cit-PAB-OH, a cleavable 4-unit PEG ADC linker, is employed in the synthesis of antibody-drug conjugates (ADCs)[1].

Boc-Val-Cit-OH is a cleavable ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs).

Thalidomide-4-OH (E3 ligase Ligand 2) (Cereblon ligand 2) is the Thalidomide-based Cereblon ligand used to recruit of CRBN protein. Thalidomide-4-OH (Cereblon ligand 2) is a linker to form PROTACs

Mal-PEG1-Val-Cit-OH is a cleavable one-unit polyethylene glycol (PEG) linker used in the synthesis of antibody-drug conjugates (ADCs) [1].

DSPE-PEG-OH (MW 2000) is a PEG-based PROTAC linker for PROTAC synthesis.

Fmoc-Val-Cit-PAB is a linker used for antibody-drug-conjugation (ADC).

MC-Val-Ala-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Boc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

MC-Val-Cit-PABC-PNP, also known as Mc-Val-Cit-PABC-PNP, is a cathepsin cleavable ADC peptide linker. For example, FDA approved drug, brentuximab vedotin, adopts this linker. Protein- and peptide-drug conjugates hold a promising stance in the delivery of therapeutic agents by providing distinct advantage of improving therapeutic potential of drugs. Use of specialized linkers makes them unique in their in vivo therapeutic application by providing target tissue-specific release of drug.

Boc-Val-Cit-PAB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Fmoc-Val-Cit-PAB-MMAE is consisted of the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.

MC-Val-Cit-PAB is a cathepsin cleavable ADC linker that is used for making antibody-drug conjugate. FDA approved drugs such as brentuximab vedotin use this linker.

Val-Cit is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Mc-Val-Cit-PAB-Cl, a cleavable ADC linker, is utilized in the conjugation of MMAE and antibodies to produce compounds such as antibody-MC-vc-MMAE (e.g., anti-CD22-MC-VC-PABC-MMAE), which demonstrate cytotoxicity with IC50s of 3.3 and 0.95 nM against BJAB and WSU cell lines, respectively.

Val-cit-PAB-OH is an ADC linker that is cleavable.

Fmoc-Val-Ala-PAB-OH (Fmoc-Val-Ala-PAB) is a useful linker for making Antibody-Drug-Conjugation (ADC) conjugate for targeting drug delivery. It is also utilized in the synthesis of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.

Mc-Val-Ala-PAB, an effective linker, is utilized in antibody-drug-conjugate (ADC).

MC-Sq-Cit-PAB-Gefitinib is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), utilizing Gefitinib—an EGFR tyrosine kinase inhibitor—connected through the MC-Sq-Cit-PAB ADC linker.

Mal-PEG1-Val-Cit-PABC-OH is a 1-unit polyethylene glycol (PEG) ADC linker with cleavable properties, used in the synthesis of antibody-drug conjugates (ADCs) to facilitate drug-antibody conjugation[1].

Azido-PEG3-Val-Cit-PAB-OH is a cleavable three-unit polyethylene glycol (PEG) antibody-drug conjugate (ADC) linker used in ADC synthesis [1].

Azido-PEG3-Val-Cit-PAB-PNP is a cleavable 3-unit PEG ADC linker used for synthesizing antibody-drug conjugates (ADCs) [1] and also functions as a PEG-based PROTAC linker for PROTAC synthesis [2].

MC(C5)-Val-Cit is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) [1].

BCN-PEG1-Val-Cit-OH is a cleavable one-unit polyethylene glycol (PEG) linker used in the synthesis of antibody-drug conjugates (ADCs) [1].

Azido-PEG4-Val-Cit-PAB-OH is a 4-unit PEG ADC linker and a PEG-based PROTAC linker used in the synthesis of antibody-drug conjugates (ADCs)[1] and PROTACs[2].

Acrylate-PEG-OH (MW 10000) is a Polyethylene Glycol (PEG)-derived PROTAC linker used in the synthesis of PROTACs[1].

HO-PEG-mal (MW 3400) is a PEG-based linker for PROTACs, joining two essential ligands necessary for forming PROTAC molecules and enabling selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

DBCO-Val-Cit-PABC-OH, a cleavable linker, is used in the synthesis of antibody-drug conjugates (ADCs) [1].

Mal-PEG-Succinimidyl Valerate (MW 20000) is a polyethylene glycol (PEG)-based linker with a molecular weight of 20000, crucial for synthesizing proteolysis targeting chimeras (PROTACs).

m-PEG-mal (MW 5000) is a PEG-based linker used in PROTACs to connect two essential ligands, facilitating selective protein degradation via the ubiquitin-proteasome system within cells.

MC-Val-Cit-PAB-Auristatin E is an antibody-drug conjugate (ADC) linker compound with Auristatin E, a potent cytotoxic tubulin modifier, attached via the MC-Val-Cit-PAB linker, demonstrating significant antitumor activity.

Mal-PEG2-Val-Cit-amido-PAB-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Mal-PEG4-Val-Cit-PAB, a cleavable ADC linker incorporating a Maleimide moiety, finds application in the construction of antibody-drug conjugates (ADCs)[1].

PDP-C1-Ph-Val-Cit is a cleavable ADC linker used in antibody-drug conjugates (ADCs).

Mal-PEG4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) therapy. It combines the ADC linker, Mal-PEG4-VC-PAB, with the potent ADC cytotoxin, DMEA-PNU-159682. The cytotoxin, DMEA-PNU-159682, is derived from metabolites of nemorubicin (MMDX) found in liver microsomes, as well as the ADC cytotoxin PNU-159682 [1].

Mal-amido-PEG2-Val-Cit-PAB-OH is a bi-functional polyethylene glycol (PEG) linker, composed of two PEG units, that is cleavable and specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1].

m-PEG-mal (MW 20000) is a PEG-based linker for PROTACs, joining two essential ligands to form PROTAC molecules and enabling selective protein degradation via the ubiquitin-proteasome system within cells.

MC-Val-Cit-PAB-carfilzomib is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADC), comprising the irreversible proteasome inhibitor carfilzomib, connected through the ADC linker MC-Val-Cit-PAB.

m-PEG-mal (MW 2000) is a PEG-based linker used in PROTACs to join two essential ligands, facilitating selective protein degradation via the ubiquitin-proteasome system within cells.

MAL-di-EG-Val-Cit-PAB-MMAE consists of the linker MAL-di-EG-Val-Cit-PAB and the potent tubulin inhibitor MMAE, both of which are crucial components of antibody-drug conjugates (ADCs).

Dioxoisoindolin-O-PEG-OH (MW 2000) is a polyethylene glycol (PEG)-based linker used in the synthesis of PROTACs (proteolysis targeting chimeras)[1].

BCN-PEG3-Val-Cit is a PEG-based linker widely used in PROTAC synthesis[1] and as a cleavable 3-unit PEG linker in the production of antibody-drug conjugates (ADCs)[2].

Fmoc-Val-Cit-PAB-Duocarmycin TM is a drug-linker conjugate intended for antibody-drug conjugation (ADC), employing the antitumor antibiotic Duocarmycin TM and connected via the linker Fmoc-Val-Cit-PAB.

m-PEG-OH (MW 2000) is a PEG-based linker for PROTACs, facilitating the connection of two essential ligands to form PROTAC molecules, thereby enabling selective protein degradation through the ubiquitin-proteasome system within cells.

Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA is an antibody-drug conjugate linker, integrating the antitumor antibiotic Duocarmycin SA via the Mal-PEG4-VC-PAB-DMEA-Seco linker, aimed at targeted cancer therapy.

MC-Val-Cit-PAB-duocarmycin is an antibody-drug conjugate (ADC) linker that combines duocarmycin, a potent DNA minor groove-binding alkylating agent, with an antitumor drug through the MC-Val-Cit-PAB linker, exhibiting significant antitumor activity.

MC-Val-Cit-PAB-clindamycin is an antibody-drug conjugate (ADC) linker combining the potent antitumor properties of clindamycin, a protein synthesis inhibitor, with the ADC linker MC-Val-Cit-PAB, thereby enhancing its cancer cell targeting and killing effectiveness.

mDPR(Boc)-Val-Cit-PAB is a cleavable linker used in antibody-drug conjugates (ADCs), which are biopharmaceuticals combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs for targeted cancer therapy [1].

SC-Val-Cit-PAB is a cleavable ADC linker for antibody-drug conjugates (ADCs).